Levothyroxine Sodium Tablets — Class II drug recall D-0701-2026
Ongoing recall by Major Pharmaceuticals, reported 2026-07-29, distributed nationwide. Subpotent Drug
| Recall number | D-0701-2026 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Ongoing |
| Voluntary or mandated | Voluntary |
| Recalling firm | Major Pharmaceuticals, Dublin, OH, United States |
| Recall initiated | 2026-07-13 |
| Classified | 2026-07-17 |
| Reported by FDA | 2026-07-29 |
| Distributed | Nationwide (US) |
| Reason classes | potency |
| NDC | 00904-6949, 00904-6949-61, 00904-6950, 00904-6950-61, 00904-6951, 00904-6951-61, 00904-6952, 00904-6952-61, 00904-6953, 00904-6953-61, 00904-6954, 00904-6954-61, 00904-6955, 00904-6955-61, 00904-6956, 00904-6956-61, 00904-6957, 00904-6957-61 |
| Lot numbers | N02200 |
| Expiration dates | 2026-10 |
Product
Levothyroxine Sodium Tablets, USP, 50 mcg (0.050 mg), 100 Tablets (10 x 10 unit dose blisters) per carton, Rx only, Packaged and Distributed by: MAJOR PHARMACEUTICALS, Indianapolis, IN 46268 USA. NDC: 0904-6950-61
Reason for recall
Subpotent Drug
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0701-2026. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.